| Human immunodeficiency virus I infection
Norvir vs Rukobia
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Norvir vs Rukobia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRukobia has a higher rate of injection site reactions vs Norvir based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rukobia but not Norvir, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Norvir
Rukobia
At A Glance
Oral
Twice daily
HIV protease inhibitor
Oral
Twice daily
HIV-1 attachment inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection (Adults) 600 mg twice daily by mouth with meals; initiate at 300 mg twice daily and increase by 100 mg q2-3 days to minimize adverse events.
Human immunodeficiency virus I infection (Pediatrics >1 month) 350-400 mg/m2 twice daily by mouth with meals, not to exceed 600 mg twice daily; initiate at 250 mg/m2 twice daily and increase by 50 mg/m2 q2-3 days.
Human immunodeficiency virus I infection 600 mg orally twice daily with or without food; swallow tablets whole, do not chew, crush, or split.
Contraindications
- Known hypersensitivity (e.g., TEN or Stevens-Johnson syndrome) to ritonavir or any excipient
- Co-administration with drugs highly dependent on CYP3A for clearance with potential for serious or life-threatening reactions: alfuzosin, ranolazine, amiodarone, dronedarone, flecainide, propafenone, quinidine, voriconazole, colchicine (renal/hepatic impairment), lurasidone, pimozide, dihydroergotamine, ergotamine, methylergonovine, cisapride, lovastatin, simvastatin, lomitapide, sildenafil (Revatio for PAH), triazolam, oral midazolam
- Co-administration with potent CYP3A inducers associated with potential loss of virologic response: apalutamide, St. John's Wort (hypericum perforatum)
- Previous hypersensitivity to fostemsavir or any component of RUKOBIA
- Coadministration with strong CYP3A inducers, including enzalutamide, carbamazepine, phenytoin, rifampin, mitotane, and St John's wort (Hypericum perforatum)
Adverse Reactions
Most common (>=1%) Diarrhea, nausea, vomiting, abdominal pain, paresthesia (including oral), rash, fatigue/asthenia, dysgeusia, coughing, arthralgia, back pain, dizziness, pruritus, myalgia, flushing, hypertriglyceridemia, peripheral neuropathy, oropharyngeal pain
Serious Hepatotoxicity, pancreatitis, allergic reactions/hypersensitivity
Postmarketing Dehydration, AV block (first-, second-, third-degree), right bundle branch block, Cushing's syndrome, adrenal suppression, seizure, nephrolithiasis, toxic epidermal necrolysis
Most common (>=2%) Nausea, diarrhea, headache, abdominal pain, dyspepsia, fatigue, rash, sleep disturbance, immune reconstitution inflammatory syndrome, somnolence, vomiting
Serious Immune reconstitution inflammatory syndrome, QTc prolongation, hepatic transaminase elevations in patients with hepatitis B or C virus co-infection
Pharmacology
Ritonavir is a peptidomimetic inhibitor of the HIV-1 protease that renders the enzyme incapable of processing the Gag-Pol polyprotein precursor, leading to production of non-infectious immature HIV particles; it also potently inhibits CYP3A and, to a lesser extent, CYP2D6, significantly affecting plasma concentrations of many co-administered drugs.
HIV-1 attachment inhibitor; fostemsavir is a prodrug hydrolyzed to temsavir, which binds directly to the gp120 subunit of the HIV-1 envelope glycoprotein and selectively inhibits the interaction between the virus and cellular CD4 receptors, preventing viral attachment and subsequent entry into host cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Norvir
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Rukobia
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Norvir
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Rukobia
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Norvir
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Rukobia
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NorvirView full Norvir profile
RukobiaView full Rukobia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.